TL;DR
This study reveals that despite the COVID-19 pandemic, antifungal prescribing in two UK hospitals remained largely driven by ingrained habits rather than evidence-based guidelines, particularly in COVID-19 patients. This highlights a critical need for improved antifungal stewardship to combat rising resistance and ensure appropriate patient care.
What Problem Does This Paper Address?
Antifungal stewardship, the responsible use of antifungal medications, is crucial for combating the growing threat of antifungal resistance. However, it often receives less attention and funding compared to antibiotic stewardship. Previous research indicates a general lack of knowledge about antifungal guidelines and a tendency for clinicians to rely on personal experience and biases when prescribing these drugs. This study aims to investigate how the COVID-19 pandemic, a significant global health event, impacted antifungal prescribing patterns in UK hospitals, specifically examining trends, the influence of the pandemic, and the balance between empirical and diagnostically guided antifungal use. The researchers want to understand if this unprecedented situation led to changes in prescribing behavior or reinforced existing practices.
Methods
The researchers conducted a retrospective cohort study analyzing inpatient antifungal usage data from two large NHS hospital trusts in South London: King's College Hospital (KCH) and Royal Brompton Hospital (RBH). They extracted data on all inpatient prescriptions for a specific list of systemic antifungals (posaconazole, voriconazole, itraconazole, isavuconazole, caspofungin, micafungin, anidulafungin, and amphotericin B) from January 2015 to December 2021. This period encompasses both pre-pandemic and pandemic years.
Key data points collected included:
- Antifungal usage: Measured as the number of distinct episodes of antifungal prescription, defined as a course lasting longer than two consecutive days.
- Location of prescription: Differentiating between intensive care units (ICUs) and other wards.
- COVID-19 status: Categorizing patients as positive, suspected, or negative for COVID-19.
- Diagnostic markers for fungal infections (in COVID-19 patients): Specifically, Aspergillus culture results, blood fungal culture results, and galactomannan test results.
The study then categorized antifungal use in COVID-19 patients into two types:
- Diagnostic-based use: When patients met at least one of the defined diagnostic criteria (positive Aspergillus culture, positive fungal blood culture, or galactomannan >0.5 nmol/mL).
- Empirical use: When antifungals were prescribed without meeting any of the diagnostic criteria.
Datasets
The study utilized electronic health records from two large NHS hospital trusts in South London: King's College Hospital NHS Foundation Trust (KCH) and the Royal Brompton Hospital, part of Guy's and St. Thomas' NHS Foundation Trust (RBH). Data spanned from January 2015 to December 2021. No new datasets were introduced.
Key Insights and Ideas
- Habitual Prescribing Dominates: The most striking finding is that even during a major health crisis like COVID-19, antifungal prescribing patterns at both trusts largely mirrored their pre-pandemic habits, rather than adapting to new guidelines or the specific challenges presented by the pandemic.
- COVID-19 Didn't Necessarily Reform Practices: While overall antifungal usage saw some fluctuations, the composition of antifungals prescribed, even within the homogenous group of COVID-19 patients, remained significantly different between the two trusts and did not consistently align with international recommendations.
- Empirical Use is Rampant: A high proportion of antifungal prescriptions in COVID-19 patients were empirical, meaning they were given without strong diagnostic evidence of fungal infection. This suggests a potential for overuse and inappropriate prescribing.
- Trust-Specific Differences Persist: Despite their geographical proximity, KCH and RBH exhibited distinct antifungal prescribing profiles, likely reflecting their different specialist services (e.g., hepatology/hematology at KCH vs. cardiorespiratory at RBH) and potentially ingrained local practices.
- Guidelines Are Not Universally Followed: The study points to a significant gap between international recommendations for treating fungal infections (especially in the context of COVID-19) and actual clinical practice in these hospitals.
Key Results
- Overall Usage Trends: Total systemic antifungal usage at KCH increased by 13% between 2015 and 2021, with a peak in 2021. RBH, however, saw a 30% decrease in usage by December 2021 compared to its 2019 peak.
- ICU Usage Spikes: Antifungal use in ICUs at KCH saw a dramatic 90% increase between 2019 and 2020, continuing to rise into 2021. RBH's ICU usage also doubled between 2017 and 2020.
- COVID-19 Patient Prescribing:
- KCH recorded 4144 COVID-19 patients, with 4% receiving antifungals.
- RBH recorded 451 COVID-19 patients, with 59% receiving antifungals.
- At RBH, of those receiving antifungals, 74% were considered empirical.
- Drug Composition Differences: Anidulafungin was the most used antifungal at KCH, while amphotericin was dominant at RBH. Voriconazole, a common first-line recommendation, was used infrequently at both sites.
- Azole Resistance: While data was only available for RBH, azole-resistant Aspergillus cultures peaked in 2019 and decreased during the COVID-19 pandemic, suggesting this was not the primary driver for high amphotericin use.
Limitations and Future Work
The authors acknowledge several limitations:
- Data Granularity: They couldn't obtain detailed medical comorbidities, making it difficult to stratify pre-pandemic antifungal use by indication (prophylaxis vs. empirical/targeted treatment) or fully understand drug choices influenced by patient factors.
- Unrelated Use: During the pandemic, it was challenging to definitively ascertain if antifungal use was solely related to COVID-19 infection or if other unrelated fungal infections were being treated.
- ICU vs. General Ward Distinction: During the pandemic, many general wards were repurposed as ICUs, making it difficult to precisely distinguish between ICU and non-ICU antifungal use.
- Diagnostic Criteria Limitations: The diagnostic criteria for categorizing antifungal use in COVID-19 patients did not include all clinical features typically used to infer probable fungal infection.
- Limited Resistance Data: Resistance data was only available for RBH, limiting broader conclusions.
Future work should focus on:
- Understanding Prescribing Behavior: More research is needed to pinpoint the exact reasons for non-adherence to guidelines, such as habitual prescribing, lack of knowledge, fear of challenging senior colleagues, or limited experience with newer antifungals.
- Developing Effective Stewardship Programs: Future interventions need to be tailored to local contexts and patient needs, and their effectiveness in improving prescribing behaviors and patient outcomes must be evaluated.
- Point-of-Care Diagnostics: Development of point-of-care assays could significantly aid in more precise and timely antifungal prescribing.
- Prospective Studies: Evaluating behaviors and factors influencing antifungal prescribing, and then assessing the impact of interventions, requires prospective study designs.
Summary updated